title: Individualized liposomal doxorubicin-based treatment in elderly patients with non-Hodgkin's lymphoma.
abstract: BACKGROUND
  We retrospectively evaluated the efficacy and safety of individualized liposomal doxorubicin-based treatment in elderly patients with non-Hodgkin's lymphoma and poor general health.
  
  
  METHODS
  22 patients (median age 83.5 years) were treated with liposomal doxorubicin combined with CHOP-based chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone) or other individualized doxorubicin-based treatments including liposomal doxorubicin combined with rituximab. Efficacy and adverse reactions were measured.
  
  
  RESULTS
  Patients received a total of 80 courses of chemotherapy (mean dose 143.6 mg/patient liposomal doxorubicin). The numbers of patients achieving complete remission, uncertain complete remission, partial remission, stable disease, or progressive disease were 10 (45.5%), 4 (18.2%), 4 (18.2%), 1 (4.5%), and 3 (13.6%), respectively. The most frequently reported adverse reaction was bone marrow suppression. No serious infections were reported. 3 (13.6%) patients showed skin changes. None experienced congestive heart failure or acute myocardial infarction. There were no chemotherapy-related deaths. Overall survival rates at 1, 3, and 5 years were 81.8, 59.1, and 40.9%, and progression-free survival rates were 83.3, 66.7, and 54.5%.
  
  
  CONCLUSIONS
  Individualized liposomal doxorubicin-based chemotherapy is effective and safe for elderly patients with non-Hodgkin's lymphoma.
authors: Department of Geriatric Hematology, General Hospital of PLA, Beijing, China.
authors: Bo
authors: B
authors: Guo
authors: Hong-Li
authors: HL
authors: Zhu
authors: Su-Xia
authors: SX
authors: Li
authors: Xue-Chun
authors: XC
authors: Lu
authors: Hui
authors: H
authors: Fan
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D057285:Precision Medicine
chemical_list: D000903:Antibiotics, Antineoplastic; D004317:Doxorubicin